Systematic Analysis of Economic Evaluation of Listed PD- 1/PD-L1 Inhibitors in China
- VernacularTitle:我国已上市PD-1/PD-L1抑制剂经济性评价的系统分析
- Author:
Yue MA
1
,
2
;
Shengwen ZHU
1
,
2
;
Lei SUN
1
,
2
;
Xin GUAN
1
,
2
;
Pingyu CHEN
1
,
2
;
Hongchao LI
1
Author Information
1. College of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Center for Pharmacoeconomics Evaluation and Research，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
PD-1/PD-L1 inhibitors;
Pharmacoeconomics;
Systematic analysis
- From:
China Pharmacy
2021;32(15):1885-1893
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To provide reference for the selection of more economical programmed death- 1（PD-1）/programmed death-ligand 1（PD-L1）inhibitors for National Medical Insurance List and the quality improvement of related economic evaluation. METHODS：Retrieved from CNKI ，VIP，Wanfang database ，PubMed，Web of Science and Ovid Embase ，economic evaluation studies including listed PD- 1/PD-L1 inhibitors of China were collected during the inception to Oct. 2020. CHEERS checklist was used to evaluate the quality of the included literatures ，and the methodological characteristics and economic evaluation results of the included studies were analyzed systematically. RESULTS ：A total of 14 literatures were included ，all of which were model-based and with moderate or high quality. However ，there were still some deficiencies in the included literatures ，mainly manifesting as the insufficient reports on the reasons for setting or selecting model parameters ，as well as the great uncertainty of clinical effect data and utility value. Only 3 of the 8 PD-1/PD-L1 inhibitors listed in China were involved in the included literatures. Compared with chemotherapy or targeted therapy plan ，9 literatures（64.29％）showed that the therapy plan containing PD- 1/PD-L1 inhibitors was not cost-effective. CONCLUSIONS ：The economic evidence of domestic PD- 1/PD-L1 inhibitors is lacking ，the higher price of imported PD- 1/PD-L1 inhibitors lead to poor economic performance. The existing economic evaluations has some shortcomings in methodological application and parameter selection. Pharmaceutical enterprises should fill in the data gaps and adjust the pricing strategy，researchers should improve the standardization of research ，and medical insurance decision-making departments should improve the judgment on the quality of economic evidences ，so as to promote more economical drugs to be included in the National Medical Insurance List.
